The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
The former England captain took to Instagram to show off his pancake flipping skills on Shrove Tuesday - and poked fun at his son's efforts.
A drier set up in the next day or so with colder air seeping in and temperatures sliding away.
Dropping 1%, the FTSE 100 index is now at levels not seen since 2012.